Mobocertinib manufacturers
- TAK-788
-
- $80.00 / 1kg
-
2024-01-02
- CAS:1847461-43-1
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
|
| | Mobocertinib Basic information |
| Product Name: | Mobocertinib | | Synonyms: | TAK-788;AP32788, MOBOCERTINIB;Mobocertinib (TAK788, AP32788);Mobocertinib;Mobocertinib (TAK788);Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate;5-Pyrimidinecarboxylic acid, 2-[[4-[[2-(dimethylamino)ethyl]methylamino]-2-methoxy-5-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester;propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate | | CAS: | 1847461-43-1 | | MF: | C32H39N7O4 | | MW: | 585.71 | | EINECS: | | | Product Categories: | API | | Mol File: | 1847461-43-1.mol |  |
| | Mobocertinib Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 10 mg/ml,DMF:PBS (pH 7.2) (1:8): 0.11 mg/ml | | form | A crystalline solid |
| | Mobocertinib Usage And Synthesis |
| Uses | Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib effectively inhibits oncogenic variants containing mutations that activate the EGFRex20ins, with selectivity superior to that of wild-type EGFR. Mobocertinib is FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) who have a HER2 mutation or an EGFR mutation, including an exon 20 insertion mutation. Mobocertinib is approved by the FDA for the treatment of patients with non-small cell lung cancer (NSCLC) who have HER2 mutations or EGFR mutations, including exon 20 insertion mutations. |
| | Mobocertinib Preparation Products And Raw materials |
|